Med. Pro Praxi 2007; 4(9): 346-347

Novinky v léčbě postmenopauzální osteoporózy

MUDr. Jiří Jenšovský
Osteocentrum, ÚVN Praha

Vzhledem k pandemickému výskytu osteoporózy v celosvětově stárnoucí populaci se do popředí zájmu dostávají otázky adherence (kompliance a perzistence) k terapii. Jedná se typicky o chronickou chorobu a jednou z možností, jak významně zvýšit adherenci k terapii, jsou nové formy léků podávané v delších časových intervalech. V léčbě osteoporózy je zatím nejnovějším postupem z tohoto hlediska podávání 150 mg ibandronátu v 1 tbl. měsíčně. Léčba je velmi dobře tolerována a prokázala významný efekt ve snižování rizika vertebrálních fraktur. V budoucnosti se budeme jistě stále častěji setkávat i s infuzní léčbou osteoporózy, např. právě ibandronátem v ještě delších časových intervalech.

Keywords: kompliance, perzistence, adherence, bisfosfonáty, ibandronát

Published: October 20, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jenšovský J. Novinky v léčbě postmenopauzální osteoporózy. Med. praxi. 2007;4(9):346-347.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis- a cross-sectional survey. Osteoporos Int 2006; 17: 1638-1644. Go to original source... Go to PubMed...
    2. Cooper A, Drake J, Brankin E et al. Treatment persistence with once- monthly ibandronate and patient support vs. once weekly alendronate- results from the PERSIST Study. Int J Clin Pract. 2006; 60 (8): 896-905. Go to original source... Go to PubMed...
    3. Cosman F, McClung M R, Rosen C J et al. Rationale and design of the MOTION Study- Monthly oral therapy with ibandronate for osteoporosis intervention. ASBMR 2007 abstrakt.
    4. Cramer JA, Amonkar MM, Hebborn A et al. Compliance and persistence with bisphosphonates dosing regiment among women with postmenoipausal osteoporosis. Curr Med Res Opin 2005; 9: 1453-1460. Go to original source... Go to PubMed...
    5. Emkey R, Koltun W, Beusterien K et al. Patient preference for one- monthly ibandronate versus once-weekly alendronate in a randomised, open label, Cross-over trial: the BonivaAlendronate Trial in Osteoporosis/BALTO/. Curr Med Res Opin 2005; 12: 1895-1903. Go to original source... Go to PubMed...
    6. Felsenberg D, Christiansen C, Czerwinsky E et al. Weekly dosing of oral ibandronate is effective in the prevention of postmenopausal osteoporosis. Osteoporos Int 2002; Suppl. 1: S 16.
    7. Chesnut Ch III, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermitently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-1249. Go to original source... Go to PubMed...
    8. McClung M, Wasnich RD, Rocker RR et al. Daily oral ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone MIner Res 2004; 19: 8-11. Go to original source... Go to PubMed...
    9. Miller PD, McClung MR, Macovei L et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE Study. J Bone Miner Res 2005; 20: 1315-1322. Go to original source... Go to PubMed...
    10. Prevention and Management of Osteoporosis. Report of a WHO Scientific Group, Ženeva 2003.
    11. Ray NF. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the NOF. J Bone Miner Res, 1997; 12: 24-35. Go to original source... Go to PubMed...
    12. Recker RR, Einstein RS, Chesnut CH III et al. Histomorphometric evaluation of daily and intermitent oral ibandronate in women with postmenopausal osteoporosis. Results from the BONE study. Osteoporos Int 2004; 15: 231-237. Go to original source... Go to PubMed...
    13. Reginster JY, Adami S, Laktos P et al. Efficacy and tolerability of once monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE Study. Ann Rheum Dis 2006; 65: 654-661. Go to original source... Go to PubMed...
    14. Simon JA, Lewiecki EM, Smith ME et al. Patient preference for once - weekly alendronate 70 mg versus once daily alendronate 10 mg: a multicenter, randomised, open label, cross over study. Clin Ther 2002; 24: 1871-1886. Go to original source... Go to PubMed...
    15. Stakkestad JA, Skag A, Norby A et al. Three monthly intravenous bolus injections: a novel treatment regiment to prezent postmenopausal bone loss. Osteoporos Int 2002; Suppl: S 17.
    16. The sex and age distributions of population. The 1994 revision of the |United Nations global population estimates and projections, New York, United Nations, 1995.
    17. Weycker D, Macarios D, Edelsberg J et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos. Int 2006; 17: 1645-1652. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.